Prepare for IPO Success in 2026

The outlook for the Initial Public Offering (IPO) market in 2026 appears increasingly promising, driven by interest rate reductions, emerging market opportunities and renewed confidence in the global economy. Analysts expect a rise in deal-making opportunities throughout the year; however, geopolitical risks and regulatory complexities continue to pose significant challenges. To navigate this environment, companies must act decisively:

  • Secure comprehensive coverage: Understand the implications of prospectus exclusions, run-off periods, and the need for new Directors' & Officers' (D&O) liability policies post-IPO. Evaluate the strategic benefits of standalone Public Offering of Securities insurance (POSI) for ring-fenced protection
  • Assess coverage limits: Evaluate your limit requirements based on market cap, sector, geographic exposure, internal governance and peer benchmarking data to determine appropriate indemnity levels
  • Plan for contingencies: Identify pre-IPO roadshow coverage conditions, U.S. listing restrictions and failure-to-launch provisions. Anticipate and address potential challenges in the event of an unsuccessful IPO

Specialist guidance for life sciences companies going public

Taking your company public is a milestone that brings exciting opportunities and complex risks. From regulatory compliance to evolving governance requirements, the journey demands a tailored risk transfer strategy that protects your business and its leadership every step of the way.

At Gallagher, we specialise in guiding life sciences organisations through this critical phase, delivering bespoke solutions for D&O, prospectus liability, and other essential coverages. Our team can help you stay protected, compliant, and ready to face the journey with confidence.

Our IPO insurance and risk transfer solutions

  • Directors' & Officers' (D&O) liability insurance: Covers claims against directors and officers resulting from their management decisions, including those related to the risks and exposures associated with Initial Public Offerings (IPOs)
  • Prospectus liability insurance: Covers claims arising from offering documents and associated disclosures
  • Cyber and data protection: Covers specific cyber and data risks arising from transactional activities related to the IPO

Insights on managing IPO risks

Explore our specialist video series on managing IPO risks, which cover the following topics:

  • How IPO-related risks are excluded under private company D&O insurance and the implications for coverage post-IPO.
  • Determining the appropriate limit of indemnity for D&O or POSI coverage before an IPO.
  • How Gallagher's D&O risk assessment service supports IPO planning through due diligence of company governance and exposures, analysis of claims data, and risk mitigation best practice recommendations.
  • Coverage restrictions for U.S. listings and inclusion of a failure to launch provision.
  • Importance of putting an IPO-specific insurance programme in place to include roadshow coverage and the value of Gallagher's expertise and data-driven guidance.

Why choose Gallagher?

At Gallagher we offer specialist expertise in IPO and public company risk mitigation, delivering tailored solutions to address the unique needs of your business. Our global presence and local market knowledge empower our specialists to provide guidance at every stage, from planning through to post-IPO risk management, ensuring your organisation is supported every step of the way.